Krystof V - Search Results

1

Cyclin-dependent kinase inhibitors as anticancer drugs.

Krystof V, Uldrijan S. Krystof V, et al. Curr Drug Targets. 2010 Mar;11(3):291-302. doi: 10.2174/138945010790711950. Curr Drug Targets. 2010. PMID: 20210754 Review.

2

Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.

Otyepka M, Krystof V, Havlícek L, Siglerová V, Strnad M, Koca J. Otyepka M, et al. Among authors: krystof v. J Med Chem. 2000 Jun 29;43(13):2506-13. doi: 10.1021/jm990506w. J Med Chem. 2000. PMID: 10891109

3

In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route.

Chmela Z, Veselý J, Lemr K, Rypka M, Hanus J, Havlícek L, Krystof V, Michnová L, Fuksová K, Lukes J. Chmela Z, et al. Among authors: krystof v. Drug Metab Dispos. 2001 Mar;29(3):326-34. Drug Metab Dispos. 2001. PMID: 11181503

4

Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.

Moravcová D, Krystof V, Havlícek L, Moravec J, Lenobel R, Strnad M. Moravcová D, et al. Among authors: krystof v. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2989-92. doi: 10.1016/s0960-894x(03)00631-0. Bioorg Med Chem Lett. 2003. PMID: 12941318

5

8-Azapurines as new inhibitors of cyclin-dependent kinases.

Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M. Havlicek L, et al. Among authors: krystof v. Bioorg Med Chem. 2005 Sep 15;13(18):5399-407. doi: 10.1016/j.bmc.2005.06.007. Bioorg Med Chem. 2005. PMID: 15993080

6

Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.

Krystof V, McNae IW, Walkinshaw MD, Fischer PM, Müller P, Vojtesek B, Orság M, Havlícek L, Strnad M. Krystof V, et al. Cell Mol Life Sci. 2005 Aug;62(15):1763-71. doi: 10.1007/s00018-005-5185-1. Cell Mol Life Sci. 2005. PMID: 16003486 Free PMC article.

7

Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.

Dolezal K, Popa I, Krystof V, Spíchal L, Fojtíková M, Holub J, Lenobel R, Schmülling T, Strnad M. Dolezal K, et al. Among authors: krystof v. Bioorg Med Chem. 2006 Feb 1;14(3):875-84. doi: 10.1016/j.bmc.2005.09.004. Epub 2005 Oct 7. Bioorg Med Chem. 2006. PMID: 16214355

8

Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.

Trávnícek Z, Krystof V, Sipl M. Trávnícek Z, et al. Among authors: krystof v. J Inorg Biochem. 2006 Feb;100(2):214-25. doi: 10.1016/j.jinorgbio.2005.07.006. Epub 2006 Jan 4. J Inorg Biochem. 2006. PMID: 16386795

9

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M. Krystof V, et al. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740. J Med Chem. 2006. PMID: 17064068

10

Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases.

Spíchal L, Krystof V, Paprskárová M, Lenobel R, Styskala J, Binarová P, Cenklová V, De Veylder L, Inzé D, Kontopidis G, Fischer PM, Schmülling T, Strnad M. Spíchal L, et al. Among authors: krystof v. J Biol Chem. 2007 May 11;282(19):14356-63. doi: 10.1074/jbc.M609750200. Epub 2007 Mar 5. J Biol Chem. 2007. PMID: 17339323 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters